RIMX
Remix Therapeutics Reports 57% Response Rate for REM-422 in Biomarker-Positive ACC Patients
Remix Therapeutics presented updated positive Phase 1 data for its oral MYB mRNA degrader REM-422 from the ARIA study in adenoid cystic carcinoma, highlighting a robust 57% overall response rate in biomarker-positive patients, a durable response, and ongoing dosing at the recommended Phase 2 dose.